// App-Quantinova.ai

BSH19‐PO‐011 : Synergistic effects of FLT3 inhibition with sorafenib and adenosine monophosphate‐activated protein kinase (AMPK) activation observed in FLT3‐ITD+ AML cells in vitro

Researchers

Presenter

  • Y. Duvieusart

Principal Investigators

  • D. MacLean

  • X. Li

  • S. Patterson

  • H. Wheadon

  • M. Copland

  • X. Huang

  • H.G. Jorgensen

Medical Centers

  • Paul O?Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • AMP-activated protein kinase

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Platelet derived growth factor

  • Fms related tyrosine kinase 3

  • Serine/threonine-protein kinase mTOR

  • Vascular endothelial growth factor A

Drug/Treatment

  • Adenosine

  • Adenosine Intravenous

  • Rapacan

  • Sorafenib

  • L-Tyrosine

  • GSK621

  • Becaplermin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved